Humana · Art Cabenuva LA · US health-plan appeal rights

Art Cabenuva LA denied as duplicate or overlapping therapy by Humana?

Q: How long do I have to appeal a Humana Art Cabenuva LA denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

If two medications appear duplicative on paper but serve different clinical purposes (e.g., short-acting vs long-acting), the appeal needs to spell out the clinical rationale for both.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-11

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Humana typically requires

Humana's specific coverage criteria for art cabenuva la are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

Source policy: Humana Medicare Part D HIV coverage

The Humana angle on Art Cabenuva LA

## Why Humana Denied Cabenuva (Long-Acting) as Duplicate Therapy

Humana's duplicate-therapy denial means their system flagged that you are already receiving antiretroviral (ART) coverage for HIV — typically a daily oral regimen — and the reviewer concluded that Cabenuva (cabotegravir + rilpivirine long-acting injectable) provides the same therapeutic function. Insurers use automated utilization-management rules to block concurrent coverage of what they categorize as overlapping drug classes.

This denial is routinely appealed and overturned. Cabenuva is not a duplicate of a daily oral ART: it is a completely distinct delivery mechanism — a monthly or every-two-month injectable combination — that serves patients for whom oral adherence is a documented clinical barrier. The FDA-approved prescribing label, your prescriber's treatment plan, and applicable HIV treatment guidelines from organizations such as DHHS (Department of Health and Human Services) together establish that injectable long-acting ART occupies a separate clinical role from oral regimens.

## Your Federal Appeal Rights

Internal appeal: Under ACA §2719 and ERISA §503, you have the right to a full-and-fair internal review. Submit your appeal in writing within the timeframe shown on your denial letter (commonly 180 days for ERISA plans).
External review: After an adverse internal decision — or after 72 hours without a decision — you may request independent external review. Federal rules give you roughly four months from the denial date to initiate external review, though your plan documents govern the exact window. An independent organization, not Humana, makes the final binding call.
Expedited option: If your prescriber documents that standard timelines would seriously jeopardize your health, request expedited external review; a decision is typically required within 72 hours.

## What to Gather

1. Diagnosis confirmation: Lab results or clinical notes confirming HIV-1 diagnosis and current virologic status. 2. Current regimen history: Documentation of every oral ART tried, with start/stop dates and outcome (tolerability issues, adherence difficulties, or persistent viremia). 3. Adherence barrier documentation: Chart notes, social-work assessments, or care-team records explaining why daily oral dosing is clinically suboptimal for you specifically. 4. Prescriber medical-necessity letter: A detailed letter explaining why Cabenuva is not duplicative but clinically distinct and necessary. 5. Humana's coverage policy: Download Humana's current published medical policy for long-acting injectable ART; note every criterion listed.

## Criteria-Mapping Structure

Build a one-page exhibit: in the left column, paste each requirement from Humana's policy verbatim. In the right column, cite the exact chart fact, date, or clinical note that satisfies it. Include a parallel column for the FDA label's indicated population. This structured mapping is the single most effective tool for an appeals reviewer and for an external reviewer who must decide whether the denial was clinically correct.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Humana appeals

Other denial reasons for Humana Art Cabenuva LA

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as experimental or investigational

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-11. Editorial standards: denialhelp.com/authors.